Leerink Partners on Monopar Therapeutics (MNPR): shares don't reflect 'magnitude of market opportunity'

March 27, 2026 4:37 PM

Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $115.00 price target on Monopar Therapeutics (NASDAQ: MNPR)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found